{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:28:32Z","timestamp":1790958512095,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":161,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642012211","type":"print"},{"value":"9783642012228","type":"electronic"}],"license":[{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/978-3-642-01222-8_10","type":"book-chapter","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T09:21:41Z","timestamp":1257499301000},"page":"131-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Decitabine"],"prefix":"10.1007","author":[{"given":"Michael","family":"Daskalakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Blagitko-Dorfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Hackanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"key":"10_CR1_10","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1200\/JCO.2007.10.8688","volume":"25","author":"K Appleton","year":"2007","unstructured":"Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Sch\u00e4tzlein A, Twelves C, Kaye SB, Brown R (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25:4603\u20134609","journal-title":"J Clin Oncol"},{"key":"10_CR2_10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0065-230X(08)60702-2","volume":"72","author":"SB Baylin","year":"1998","unstructured":"Baylin SB, Herman JG, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Cancer Res 72:141\u2013196","journal-title":"Cancer Res"},{"key":"10_CR3_10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1044-579X(02)00053-6","volume":"12","author":"SB Baylin","year":"2002","unstructured":"Baylin SB (2002) Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 12:331\u2013337","journal-title":"Semin Cancer Biol"},{"key":"10_CR4_10","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2005.16.600","volume":"23","author":"KN Bhalla","year":"2005","unstructured":"Bhalla KN (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23:3971\u20133993","journal-title":"J Clin Oncol"},{"key":"10_CR5_10","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","volume":"25","author":"W Blum","year":"2007","unstructured":"Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25:3884\u20133891","journal-title":"J Clin Oncol"},{"key":"10_CR6_10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1517\/14712598.2.6.577","volume":"2","author":"B Bodey","year":"2002","unstructured":"Bodey B (2002) Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin Biol Ther 2:577\u2013584","journal-title":"Expert Opin Biol Ther"},{"key":"10_CR7_10","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1634\/stemcells.2008-0377","volume":"26","author":"C Bogani","year":"2008","unstructured":"Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, Le Bousse-Kerdiles MC, Barosi G, Vannucchi AM; Myeloproliferative Disorders Research Consortium (2008) Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 26: 1920\u20131930","journal-title":"Stem Cells"},{"key":"10_CR8_10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00001813-200209000-00013","volume":"13","author":"AJ Boivin","year":"2002","unstructured":"Boivin AJ, Momparler LF, Hurtubise A, Momparler RL (2002) Antineoplastic action of 5-aza-2\u2019-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 13:869\u2013874","journal-title":"Anticancer Drugs"},{"key":"10_CR9_10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/10428190701882146","volume":"49","author":"G Borthakur","year":"2008","unstructured":"Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Katarjian H (2008) Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49:690\u2013695","journal-title":"Leuk Lymphoma"},{"key":"10_CR10_10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0026-895X(25)14371-X","volume":"24","author":"J Bouchard","year":"1983","unstructured":"Bouchard J, Momparler RL (1983) Incorporation of 5-aza-2\u2019-deoxycytidine 5\u2019-triphosphate into DNA. Interactions with mammalian DNA polymerase and DNA methylase. Mol Pharmacol 24:109\u2013114","journal-title":"Mol Pharmacol"},{"key":"10_CR11_10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/jcp.20133","volume":"202","author":"L Calabro","year":"2005","unstructured":"Calabro L, Fonsatti E, Altomonte M, Pezzani L, Colizzi F, Nanni P, Gattei V, Sigalotti L, Maio M (2005) Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J Cell Physiol 202:474\u2013477","journal-title":"J Cell Physiol"},{"key":"10_CR12_10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","volume":"21","author":"EE Cameron","year":"1999","unstructured":"Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103\u2013107","journal-title":"Nat Genet"},{"key":"10_CR13_10","doi-asserted-by":"crossref","unstructured":"Cashen A, Schiller GJ, Larsen JS, Cullen MT, DiPersio JF (2006) Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML). Blood 108:abstr. 1984","DOI":"10.1182\/blood.V108.11.1984.1984"},{"key":"10_CR14_10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-007-0531-7","volume":"61","author":"AF Cashen","year":"2008","unstructured":"Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J (2008) Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 61:759\u2013766","journal-title":"Cancer Chemother Pharmacol"},{"key":"10_CR15_10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jnci\/95.5.399","volume":"95","author":"JC Cheng","year":"2003","unstructured":"Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95:399\u2013409","journal-title":"J Natl Cancer Inst"},{"key":"10_CR16_10","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1128\/MCB.24.3.1270-1278.2004","volume":"24","author":"JC Cheng","year":"2004","unstructured":"Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24:1270\u20131278","journal-title":"Mol Cell Biol"},{"key":"10_CR17_10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2141.2007.06707.x","volume":"138","author":"SH Choi","year":"2007","unstructured":"Choi SH, Byun HM, Kwan JM, Issa JP, Yang AS (2007) Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol 138: 616\u2013623","journal-title":"Br J Haematol"},{"key":"10_CR18_10","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/1535-7163.MCT-05-0172","volume":"4","author":"JC Chuang","year":"2005","unstructured":"Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS, Jones PA (2005) Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2\u2019-deoxycytidine. Mol Cancer Ther 4:1515\u20131520","journal-title":"Mol Cancer Ther"},{"key":"10_CR19_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00002371-199901000-00003","volume":"22","author":"S Coral","year":"1999","unstructured":"Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M (1999) Prolonged upregulation of the expression of HLA class I antigens and costimulatory \u00admolecules on melanoma cells treated with 5-aza-2\u2019-deoxycytidine (5-AZA-CdR). J Immunother 22: 16\u201324","journal-title":"J Immunother"},{"key":"10_CR20_10","first-page":"2690","volume":"8","author":"S Coral","year":"2002","unstructured":"Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M (2002) 5-aza-2\u2019-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Cancer Res 8: 2690\u20132695","journal-title":"Cancer Res"},{"key":"10_CR21_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jcp.20540","volume":"207","author":"S Coral","year":"2006","unstructured":"Coral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E, Pezzani L, Fratta E, Fonsatti E, Di Giacomo AM, Nicotra MR, Natali PG, Altomonte M, Maio M (2006) Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol 207: 58\u201366","journal-title":"J Cell Physiol"},{"key":"10_CR22_10","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0021-9258(19)68144-5","volume":"257","author":"F Creusot","year":"1982","unstructured":"Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentation by 5-azacytidine and 5-aza-2\u2019-deoxycytidine. J Biol Chem 257:2041\u20132048","journal-title":"J Biol Chem"},{"key":"10_CR23_10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2141.2008.07541.x","volume":"145","author":"AV Danilov","year":"2009","unstructured":"Danilov AV, Relias V, Feeney DM, Miller KB (2009) Decitabine is an effective treatment of idiopathic myelofibrosis (correspondence). Brit J Haematol 145:131\u2013132","journal-title":"Brit J Haematol"},{"key":"10_CR24_10","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","volume":"100","author":"M Daskalakis","year":"2002","unstructured":"Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA, L\u00fcbbert M (2002) Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\u2019-deoxycytidine (decitabine) treatment. Blood 100:2957\u20132964","journal-title":"Blood"},{"key":"10_CR25_10","first-page":"131","volume-title":"5-Aza-2\u2019-deoxycytidine: preclinical and clinical studies","author":"L Debusscher","year":"1990","unstructured":"Debusscher L, Marie JP, Dodion P, Blanc GM, Arrigo C, Zittoun R, Stryckmans P (1990) Phase-I-II trial of 5-aza-2\u2019-deoxycytidine in adult patients with acute leukemia. In: Momparler RL, de Vos D (eds) 5-Aza-2\u2019-deoxycytidine: preclinical and clinical studies. PCH, Haarlem, The Netherlands, pp 131\u2013142"},{"key":"10_CR26_10","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/cncr.11184","volume":"97","author":"M De Lima","year":"2003","unstructured":"De Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H (2003) Long-term follow up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97:1242\u20131247","journal-title":"Cancer"},{"key":"10_CR27_10","doi-asserted-by":"crossref","unstructured":"De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson, J, Garcia-Manero G, Champlin R, Issa J-P, Ravandi F (2009) Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43:839\u2013843","DOI":"10.1038\/bmt.2008.400"},{"key":"10_CR28_10","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood.V99.11.3905","volume":"99","author":"J DeSimone","year":"2002","unstructured":"DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, Talischy N (2002) Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99:3905\u20133908","journal-title":"Blood"},{"key":"10_CR29_10","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1128\/MCB.19.11.7327","volume":"19","author":"De Smet","year":"1999","unstructured":"De Smet C, Lurquin C, Lethe B, Martelange V, Boon T (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19:7327\u20137335","journal-title":"Mol Cell Biol"},{"key":"10_CR30_10","first-page":"3197","volume":"45","author":"M D\u2019Incalci","year":"1985","unstructured":"D\u2019Incalci M, Covey JM, Zaharko DS, Kohn KW (1985) DNA alkali-labile sites induced by incorporation of 5-aza-2\u2019-deoxycytidine into DNA of mouse leukemia L1210 cells. Cancer Res 45: 3197\u20133202","journal-title":"Cancer Res"},{"key":"10_CR31_10","first-page":"117","volume-title":"5-Aza-2\u2019-deoxycytidine: preclinical and clinical studies","author":"PF Dodion","year":"1990","unstructured":"Dodion PF, Clavel M, Ten Bokkel Huinink W, Robinson E, Renard JF (1990) Phase-II trials with 2\u2019-deoxy-5-azacytidine conducted by the early clinical trials group of the EORTC. In: Momparler RL, de Vos D (eds) 5-Aza-2\u2019-deoxycytidine: preclinical and clinical studies. PCH, Haarlem, pp 117\u2013124"},{"key":"10_CR32_10","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1021\/jm00115a017","volume":"34","author":"JS Driscoll","year":"1991","unstructured":"Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, Barchi JJ Jr (1991) Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem 34:3280\u20133284","journal-title":"J Med Chem"},{"key":"10_CR33_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR (2007) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31\u201339","journal-title":"Blood"},{"issue":"4","key":"10_CR34_10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrg2005","volume":"8","author":"M Esteller","year":"2007","unstructured":"Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8(4):286\u2013298","journal-title":"Nat Rev Genet"},{"key":"10_CR35_10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"M Esteller","year":"2008","unstructured":"Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148\u20131159","journal-title":"N Engl J Med"},{"key":"10_CR36_10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.blre.2006.01.002","volume":"20","author":"H Fathallah","year":"2006","unstructured":"Fathallah H, Atweh GF (2006) DNA hypomethylation therapy for hemoglobin disorders: molecular mechanisms and clinical application. Blood Rev 20:227\u2013234","journal-title":"Blood Rev"},{"key":"10_CR37_10","first-page":"806","volume":"6","author":"H Fathallah","year":"2008","unstructured":"Fathallah H (2008) DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O]. Clin Adv Hematol Oncol 6:806\u2013808","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"10_CR38_10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4161\/cbt.8.10.8213","volume":"8","author":"W Fiskus","year":"2009","unstructured":"Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, Wang Y, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Atadja P, Bhalla KN (2009) Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther 8(10):939\u2013950","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"10_CR39_10","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/leu.2008.397","volume":"23","author":"C Flotho","year":"2009","unstructured":"Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, L\u00fcbbert M (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23(6): 1019\u20131028","journal-title":"Leukemia"},{"key":"10_CR40_10","first-page":"2217","volume":"8","author":"G Garcia-Manero","year":"2002","unstructured":"Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP (2002a) DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8:2217\u20132224","journal-title":"Clin Cancer Res"},{"key":"10_CR41_10","first-page":"1897","volume":"8","author":"G Garcia-Manero","year":"2002","unstructured":"Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP (2002b) DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res 8: 1897\u20131903","journal-title":"Clin Cancer Res"},{"key":"10_CR42_10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/cncr.11090","volume":"3","author":"G Garcia-Manero","year":"2003","unstructured":"Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian HM, Issa JP (2003) Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer 3:695\u2013702","journal-title":"Cancer"},{"key":"10_CR43_10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/07357900500283119","volume":"23","author":"G Garcia-Manero","year":"2005","unstructured":"Garcia-Manero G, Issa JP (2005) Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 23: 635\u2013642","journal-title":"Cancer Invest"},{"key":"10_CR44_10","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Yang H, Sanchez-Gonzalez B, Verstovsek S, Ferrajoli A, Keating M, Andreeff M, O\u2019Brien S, Cortes J, Wierda W, Faderl S, Koller C, Davis J, Morris G, Issa JP, Frankel SR, Richon V, Fine B, Kantarjian H (2005) Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome. Blood 106:abstr. 2801","DOI":"10.1182\/blood.V106.11.2801.2801"},{"key":"10_CR45_10","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","volume":"108","author":"G Garcia-Manero","year":"2006","unstructured":"Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O\u2019brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP (2006) Phase 1\/2 study of the combination of 5-aza-2\u2019-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271\u20133279","journal-title":"Blood"},{"key":"10_CR46_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.seminhematol.2008.09.008","volume":"46","author":"G Garcia-Manero","year":"2009","unstructured":"Garcia-Manero G, Yang H, Kuang SQ, O\u2019Brien S, Thomas D, Kantarjian H (2009) Epigenetics of acute lymphocytic leukemia. Semin Hematol 46: 24\u201332","journal-title":"Semin Hematol"},{"key":"10_CR47_10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/j.seminoncol.2005.07.006","volume":"32","author":"V Gattei","year":"2005","unstructured":"Gattei V, Fonsatti E, Sigalotti L, Degan M, Di Giacomo AM, Altomonte M, Calabro L, Maio M (2005) Epigenetic immunomodulation of hematopoietic malignancies. Semin Oncol 32: 503\u2013510","journal-title":"Semin Oncol"},{"key":"10_CR48_10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood-2007-03-080903","volume":"110","author":"AA Giagounidis","year":"2007","unstructured":"Giagounidis AA (2007) Decitabine dosage in myelodysplastic syndromes. Blood 110:1082\u20131083","journal-title":"Blood"},{"issue":"Suppl 1","key":"10_CR49_10","first-page":"32","volume":"11","author":"S Giralt","year":"1997","unstructured":"Giralt S, Davis M, O\u2019Brien S, Van Besien K, Champlin R, De Vos D, Kantarjian H (1997) Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia 11(Suppl 1):32\u201334","journal-title":"Leukemia"},{"key":"10_CR50_10","unstructured":"Giralt S, Cohen A, Davis M, O\u2019Brien S, Andersson B, Gajewski J, Khouri I, K\u00f6rbling M, Champlin R, De Vos D, Kantarjian H (1998a) Phase-I\/II study of decitabine with allogeneic peripheral blood stem cell transplantation for treatment of relapse after allogeneic progenitor cell transplantation. Symposium on methyltransferase inhibitors in hematologic malignancies, Miami, FL, December 1998 (abstract)"},{"key":"10_CR51_10","unstructured":"Giralt S, Cohen A, Davis M, O\u2019Brien S, Andersson B, Gajewski J, Khouri I, K\u00f6rbling M, Champlin R, De Vos D, Kantarjian H (1998b) Phase-I\/II trial combining decitabine with busulfan\/cyclophosphamide as a conditioning regimen for allogeneic progenitor cell transplantation. Symposium on methyltransferase inhibitors in hematologic malignancies, Miami, December 1998 (abstract)"},{"key":"10_CR52_10","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1158\/1078-0432.CCR-06-0883","volume":"12","author":"JA Gollob","year":"2006","unstructured":"Gollob JA, Sclambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressmann HK, Jelinek J, Issa JP (2006) Phase I trial of sequential low-dose 5-aza-2\u2019-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12:4619\u20134627","journal-title":"Clin Cancer Res"},{"key":"10_CR53_10","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","volume":"66","author":"SD Gore","year":"2006","unstructured":"Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361\u20136369","journal-title":"Cancer Res"},{"key":"10_CR54_10","first-page":"4831","volume":"46","author":"CJ Groeningen","year":"1986","unstructured":"Groeningen CJ, Leyva A, O\u2019Brien Ann MP, Gall HE, Pinedo HM (1986) Phase-I and pharmacokinetic study of 5-aza-2\u2019-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46:4831\u20134836","journal-title":"Cancer Res"},{"key":"10_CR55_10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/0008-5472.CAN-05-3020","volume":"66","author":"ZS Guo","year":"2006","unstructured":"Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS (2006) De novo induction of a cancer\/testis antigen by 5-aza-2\u2019-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 66:1105\u20131113","journal-title":"Cancer Res"},{"key":"10_CR56_10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1182\/blood-2007-11-125492","volume":"112","author":"L Hambach","year":"2008","unstructured":"Hambach L, Vermeij M, Buser A, Aghai Z, van der Kwast T, Goulmy E (2008) Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood 112:1844\u20131852","journal-title":"Blood"},{"key":"10_CR57_10","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2008-05-158956","volume":"113","author":"L Hambach","year":"2009","unstructured":"Hambach L, Ling KW, Pool J, Aghai Z, Blokland E, Tanke HJ, Bruijn JA, Halfwerk H, van Boven H, Wieles B, Goulmy E (2009) Hypomethylation drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood 113:2715\u20132722","journal-title":"Blood"},{"key":"10_CR58_10","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2005-05-2033","volume":"107","author":"M Herranz","year":"2006","unstructured":"Herranz M, Martin-Caballero J, Fraga MF, Ruiz-Cabello J, Flores JM, Desco M, Marquez VE, Esteller M (2006) The novel DNA methylation inhibitor zebularine is effective against the development of T-cell lymphoma. Blood 107:1174\u20131177","journal-title":"Blood"},{"key":"10_CR59_10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/sj.leu.2404615","volume":"21","author":"K Hoshino","year":"2007","unstructured":"Hoshino K, Quint\u00e1s-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G (2007) Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 21:906\u2013911","journal-title":"Leukemia"},{"key":"10_CR60_10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/sj.bjc.6602881","volume":"93","author":"I Hubeek","year":"2005","unstructured":"Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ (2005) The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 93:1388\u20131394","journal-title":"Br J Cancer"},{"key":"10_CR61_10","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","volume":"23","author":"JP Issa","year":"2005","unstructured":"Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM (2005) Phase II study of low dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23:3948\u20133956","journal-title":"J Clin Oncol"},{"key":"10_CR62_10","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.1038\/sj.onc.1207510","volume":"23","author":"LC Jones","year":"2004","unstructured":"Jones LC, Tefferi A, Idos GE, Kumagai T, Hofmann WK, Koeffler HP (2004) RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene 23: 7846\u20137853","journal-title":"Oncogene"},{"key":"10_CR63_10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683\u2013692","journal-title":"Cell"},{"key":"10_CR64_10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","volume":"82","author":"HM Kantarjian","year":"1993","unstructured":"Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M (1993) Chronic myelogenous leukemia: a concise update. Blood 82:691\u2013703","journal-title":"Blood"},{"issue":"Suppl 1","key":"10_CR65_10","first-page":"35","volume":"11","author":"HM Kantarjian","year":"1997","unstructured":"Kantarjian HM, O\u2019Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, De Vos D, Talpaz M (1997a) Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 11(Suppl 1):35\u201336","journal-title":"Leukemia"},{"key":"10_CR66_10","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/sj.leu.2400796","volume":"11","author":"HM Kantarjian","year":"1997","unstructured":"Kantarjian HM, O\u2019Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, De Vos D, Talpaz M (1997b) Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11:1617\u20131620","journal-title":"Leukemia"},{"key":"10_CR67_10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","volume":"98","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M (2003) Results of decitabine (5-aza-2\u2019-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98:522\u2013528","journal-title":"Cancer"},{"key":"10_CR68_10","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794\u20131803","journal-title":"Cancer"},{"key":"10_CR69_10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","volume":"109","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Oki Y, Garcia-Manero G, Huang X, O\u2019Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP (2007a) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52\u201357","journal-title":"Blood"},{"key":"10_CR70_10","doi-asserted-by":"crossref","first-page":"42a","DOI":"10.1182\/blood.V110.11.42.42","volume":"110","author":"H Kantarjian","year":"2007b","unstructured":"Kantarjian H, Garcia-Manero G, O\u2019Brien S, Estrov Z, Ravandi F, Cortes J, Shan J, Davisson J, Issa JP (2007b) Survival and efficacy of decitabine in myelodysplastic syndromes (MDS), analysis of the 5-day iv dosing regimen. Blood 110:42a (abstract 115)","journal-title":"Blood"},{"issue":"Suppl","key":"10_CR71_10","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1007\/PL00014050","volume":"46","author":"A Knuth","year":"2000","unstructured":"Knuth A, J\u00e4ger D, J\u00e4ger E (2000) Cancer immunotherapy in clinical oncology. Cancer Chemother Pharmacol 46(Suppl):S46\u2013S51","journal-title":"Cancer Chemother Pharmacol"},{"key":"10_CR72_10","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood.V96.7.2379","volume":"96","author":"M Koshy","year":"2000","unstructured":"Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J (2000) 2-deoxy-5\u2019-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96:2379\u20132384","journal-title":"Blood"},{"key":"10_CR73_10","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/leu.2008.130","volume":"8","author":"SQ Kuang","year":"2008","unstructured":"Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G (2008) Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphoblastic leukemia. Leukemia 8: 1529\u20131538","journal-title":"Leukemia"},{"key":"10_CR74_10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","volume":"104","author":"A Kuendgen","year":"2004","unstructured":"Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in \u00adcombination with all-trans retinoic acid. Blood 104: 1266\u20131269","journal-title":"Blood"},{"key":"10_CR75_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00686478","volume":"30","author":"J Lalibert\u00e9","year":"1992","unstructured":"Lalibert\u00e9 J, Marquez VE, Momparler RL (1992) Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2\u2019-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 30:7\u201311","journal-title":"Cancer Chemother Pharmacol"},{"key":"10_CR76_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2004.08.002","volume":"41","author":"DE Lavelle","year":"2004","unstructured":"Lavelle DE (2004) The molecular mechanism of fetal hemoglobin reactivation. Semin Hematol 41:3\u201310","journal-title":"Semin Hematol"},{"key":"10_CR77_10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.21020","volume":"82","author":"D Lavelle","year":"2007","unstructured":"Lavelle D, Chin J, Vaitkus K, Redkar S, Phiasivongsa P, Tang C, Will R, Hankewych M, Roxas B, Singh M, Saunthararajah Y, Desimone J (2007) Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. Am J Hematol 82:981\u2013985","journal-title":"Am J Hematol"},{"key":"10_CR78_10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00001813-200503000-00009","volume":"16","author":"M Lemaire","year":"2005","unstructured":"Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL (2005) Enhancement of antineoplastic action of 5-aza-2\u2019-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 16:301\u2013308","journal-title":"Anticancer Drugs"},{"key":"10_CR79_10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00280-008-0750-6","volume":"63","author":"M Lemaire","year":"2009","unstructured":"Lemaire M, Momparler LF, Raynal NJM, Bernstein ML, Momparler RL (2009) Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2\u2019-deoxycytidine. Cancer Chemother Pharmacol 63:411\u2013416","journal-title":"Cancer Chemother Pharmacol"},{"key":"10_CR80_10","first-page":"135","volume":"249","author":"M L\u00fcbbert","year":"2000","unstructured":"L\u00fcbbert M (2000) DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Topics Microbiol Immunol 249:135\u2013164","journal-title":"Curr Topics Microbiol Immunol"},{"key":"10_CR81_10","first-page":"349","volume":"114","author":"M L\u00fcbbert","year":"2001","unstructured":"L\u00fcbbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with DNA methylation inhibitor 5-aza-2\u2019-deoxycytidine. Br J Haematol 114:349\u2013357","journal-title":"Br J Haematol"},{"key":"10_CR82_10","first-page":"905a","volume":"104","author":"M L\u00fcbbert","year":"2004","unstructured":"L\u00fcbbert M, Wijermans PW, R\u00fcter BH (2004) Re-treatment with low-dose 5-Aza-2\u2019-deoxycytidine (decitabine) results in second remissions of previously responsive MDS patients. Blood 104:905a (abstract 406)","journal-title":"Blood"},{"key":"10_CR83_10","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1182\/blood.V106.11.1852.1852","volume":"106","author":"M L\u00fcbbert","year":"2005","unstructured":"L\u00fcbbert M, R\u00fcter B, Schmid M, Sabine Knipp, Ulrich Germing, Christiane Dobbelstein, Hartmut Eimermacher, Barbara Deschler, Rainer Claus, Richard Schlenk, Arnold Ganser, Hartmut D\u00f6hner, Claudia Schmoor, and Hartmut Hen\u00df (2005) Continued low-dose decitabine (DAC) is an active first line treatment of older AML patients: first results of a multicenter phase II study. Blood 106:1852 (abstract 527)","journal-title":"Blood"},{"key":"10_CR84_10","doi-asserted-by":"crossref","unstructured":"L\u00fcbbert M, Bertz H, R\u00fcter B, Marks R, Claus R, W\u00e4sch R, Finke J (2009) Non-intensive treatment with low-dose 5-aza-2\u2019-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS\/AML-patients. Bone Marrow Transplant 2009, Apr. 13, epub ahead of print","DOI":"10.1038\/bmt.2009.64"},{"key":"10_CR85_10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/jnci\/dji311","volume":"97","author":"F Lyko","year":"2005","unstructured":"Lyko F, Brown R (2005) DNA methyltransferase inhibitors and the establishment of epigenetic cancer therapies. J Natl Cancer Inst 97:1498\u20131506","journal-title":"J Natl Cancer Inst"},{"key":"10_CR86_10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1196\/annals.1359.037","volume":"1058","author":"VE Marquez","year":"2005","unstructured":"Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA (2005) Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci 1058:246\u2013254","journal-title":"Ann N Y Acad Sci"},{"key":"10_CR87_10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.leu.2404050","volume":"2","author":"P Maslak","year":"2006","unstructured":"Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2:212\u2013217","journal-title":"Leukemia"},{"key":"10_CR88_10","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0006-2952(79)90454-4","volume":"28","author":"RL Momparler","year":"1979","unstructured":"Momparler RL, Derse D (1979) Kinetics of phosphorylation of 5-aza-2\u2019-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 28:1443\u20131444","journal-title":"Biochem Pharmacol"},{"key":"10_CR89_10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/0145-2126(85)90123-7","volume":"9","author":"RL Momparler","year":"1985","unstructured":"Momparler RL, Bouchard J, Samson J (1985a) Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-aza-2\u2019-deoxycytidine. Leuk Res 9: 1361\u20131366","journal-title":"Leuk Res"},{"key":"10_CR90_10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0163-7258(85)90052-X","volume":"30","author":"RL Momparler","year":"1985","unstructured":"Momparler RL, Rivard GE, Gyger M (1985b) Clinical trial on 5-aza-2\u2019-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30:277\u2013286","journal-title":"Pharmacol Ther"},{"key":"10_CR91_10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00001813-199704000-00008","volume":"8","author":"RL Momparler","year":"1997","unstructured":"Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J (1997) Pilot phase-I-II study on 5-aza-2\u2019-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8:358\u2013368","journal-title":"Anticancer Drugs"},{"key":"10_CR92_10","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.4161\/cbt.5.11.3299","volume":"5","author":"AJ Montero","year":"2006","unstructured":"Montero AJ, Diaz-Montero CM, Mao L, Youssef EM, Estecio M, Shen L, Issa JP (2006) Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biol Ther 5:1494\u20131501","journal-title":"Cancer Biol Ther"},{"key":"10_CR93_10","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1158\/0008-5472.CAN-05-0695","volume":"65","author":"C Mund","year":"2005","unstructured":"Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F (2005) Characterization of DNA demethylation effects induced by 5-Aza-2\u2019-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 65: 7086\u20137090","journal-title":"Cancer Res"},{"key":"10_CR94_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4161\/epi.1.1.2375","volume":"1","author":"C Mund","year":"2006","unstructured":"Mund C, Brueckner B, Lyko F (2006) Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 1:7\u201313","journal-title":"Epigenetics"},{"key":"10_CR95_10","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1002\/ijc.23407","volume":"122","author":"A Natsume","year":"2008","unstructured":"Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, Kondo Y, Sekido Y, Kawatsura H, Narita Y, Yoshida J (2008) The DNA demethylating agent 5-aza-2\u2019-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 122:2542\u20132553","journal-title":"Int J Cancer"},{"key":"10_CR96_10","doi-asserted-by":"crossref","first-page":"317b","DOI":"10.1182\/blood.V108.11.317.317","volume":"108","author":"OM Odenike","year":"2006","unstructured":"Odenike OM, Godwin JE, van Besien K, Huo D, Stiff PJ, Sher D, Klekowski N, Green M, Larson RA, Stock W (2006) Phase II study of decitabine in myelofibrosis with myeloid metaplasia. Blood 108:317b (abstract 4923)","journal-title":"Blood"},{"key":"10_CR97_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11060-008-9732-0","volume":"92","author":"S Oi","year":"2009","unstructured":"Oi S, Natsume A, Ito M, Kondo Y, Shimato S, Maeda Y, Saito K, Wakabayashi T (2009) Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2\u2019-deoxycytidine in glioma cells. J Neurooncol 92:15\u201322","journal-title":"J Neurooncol"},{"key":"10_CR98_10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","volume":"109","author":"Y Oki","year":"2007","unstructured":"Oki Y, Kantarjian H, Gharibyan V, Jones D, O\u2019brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP (2007) Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109:899\u2013906","journal-title":"Cancer"},{"key":"10_CR99_10","first-page":"36","volume":"7","author":"MC Petti","year":"1993","unstructured":"Petti MC, Mandelli F, Zagonel V, De Gregoris C, Merola MC, Latagliata R, Gattei V, Fazi P, Monfardini S, Pino A (1993) Pilot study of 5-aza-2\u2019-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 7:36\u201341","journal-title":"Leukemia"},{"key":"10_CR100_10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V64.4.922.922","volume":"64","author":"A Pinto","year":"1984","unstructured":"Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP (1984) 5-Aza-2\u2019-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922\u2013929","journal-title":"Blood"},{"issue":"Suppl 3","key":"10_CR101_10","first-page":"28","volume":"4","author":"A Pinto","year":"1989","unstructured":"Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A, Monfardini S, Colombatti A (1989) 5-Aza-2\u2019-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 4(Suppl 3):28\u201332","journal-title":"Bone Marrow Transplant"},{"key":"10_CR102_10","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1135\/cccc19642576","volume":"29","author":"J Pliml","year":"1964","unstructured":"Pliml J, Sorm F (1964) Synthesis of 2\u2019-deoxy-D-ribofuranosyl-5-azacytosine. Coll Czeck Chem Commun 29:2576\u20132577","journal-title":"Coll Czeck Chem Commun"},{"key":"10_CR103_10","first-page":"6039","volume":"60","author":"JA Plumb","year":"2000","unstructured":"Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R (2000) Reversal of drug resistance in human tumor xenografts by 2\u2019deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60:6039\u20136044","journal-title":"Cancer Res"},{"key":"10_CR104_10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000421-200210000-00015","volume":"25","author":"P Pohlmann","year":"2002","unstructured":"Pohlmann P, DiLeone LP, Cancella AI, Caldas AP, Dal Lago L, Campos O Jr, Monega E, Rivoire W, Schwartsmann G (2002) Phase II trial of cisplatin plus decitabine, a new hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 25:496\u2013501","journal-title":"Am J Clin Oncol"},{"key":"10_CR105_10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.bmt.1703028","volume":"27","author":"F Ravandi","year":"2001","unstructured":"Ravandi F, Kantarjian H, Cohen A, Davis M, O\u2019Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S (2001) Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27: 1221\u20131225","journal-title":"Bone Marrow Transplant"},{"key":"10_CR106_10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/bjc.1991.258","volume":"64","author":"DJ Richel","year":"1991","unstructured":"Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R (1991) The antileukemic activity of 5-aza-2\u2019-\u00addeoxycytidine (Aza-dC) in patients with relapsed and resistant leukemia. Br J Cancer 64:144\u2013148","journal-title":"Br J Cancer"},{"key":"10_CR107_10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0145-2126(81)90116-8","volume":"5","author":"GE Rivard","year":"1981","unstructured":"Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K, Momparler LF (1981) Phase I study on 5-aza-2\u2019-deoxycytidine in children with acute leukemia. Leuk Res 5:453\u2013462","journal-title":"Leuk Res"},{"key":"10_CR108_10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1182\/blood-2004-03-0954","volume":"10","author":"J Roman-Gomez","year":"2004","unstructured":"Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz MJ, Prosper F, Heiniger A, Torres A (2004) Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 10:2492\u20132498","journal-title":"Blood"},{"key":"10_CR109_10","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1182\/blood-2006-09-047043","volume":"8","author":"J Roman-Gomez","year":"2007","unstructured":"Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L, Calasanz MJ, Heiniger A, Torres A, Prosper F (2007a) Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 8:3462\u20133469","journal-title":"Blood"},{"key":"10_CR110_10","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1080\/10428190701344899","volume":"48","author":"J Roman-Gomez","year":"2007","unstructured":"Roman-Gomez J, Jimenez-Velasco A, Barrios M, Prosper F, Heiniger A, Torres A, Agirre X (2007b) Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk Lymphoma 48:1269\u20131282","journal-title":"Leuk Lymphoma"},{"key":"10_CR111_10","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/cncr.21796","volume":"106","author":"B R\u00fcter","year":"2006","unstructured":"R\u00fcter B, Wijermans PW, L\u00fcbbert M (2006) Superiority of prolonged low-dose azanucleoside administration ? Results of 5-aza-2\u2019-deoxycytidine retreatment in high risk myelodysplasia patients. Cancer 106:1744\u20131750","journal-title":"Cancer"},{"key":"10_CR112_10","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood-2007-03-080630","volume":"110","author":"B R\u00fcter","year":"2007","unstructured":"R\u00fcter B, Wijermans P, Claus R, Kunzmann R, L\u00fcbbert M (2007) Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with chromosome 7 abnormalities. Blood 110:1080\u20131082","journal-title":"Blood"},{"issue":"Suppl 1","key":"10_CR113_10","first-page":"252a","volume":"92","author":"S Sacchi","year":"1998","unstructured":"Sacchi S, Talpaz M, O\u2019Brien S, Cortes J, Kantarjian HM (1998) Decitabine, a hypomethylating agent, is active for the treatment of chronic myelogenous leukemia (CML) in non-lymphoid blastic phase (BP). Blood 92 (Suppl 1):252a (abstract)","journal-title":"Blood"},{"key":"10_CR114_10","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","volume":"86","author":"S Sacchi","year":"1999","unstructured":"Sacchi S, Kantarjian HM, O\u2019Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M (1999) Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86:2632\u20132641","journal-title":"Cancer"},{"key":"10_CR115_10","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.2005.06.118","volume":"23","author":"WE Samlowski","year":"2005","unstructured":"Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR (2005) Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 23:3897\u20133905","journal-title":"J Clin Oncol"},{"key":"10_CR116_10","first-page":"83","volume":"83","author":"DV Santi","year":"1983","unstructured":"Santi DV, Garret CD, Barr PJ (1983) On the mechanism of inhibition of DNA-cytosine methyltransferase by cytidine analogs. Cell 83:83\u201389","journal-title":"Cell"},{"key":"10_CR117_10","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","volume":"102","author":"Y Saunthararajah","year":"2003","unstructured":"Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J (2003) Effects of 5-aza-2\u2019-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102:3865\u20133870","journal-title":"Blood"},{"key":"10_CR118_10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/08880010701558188","volume":"24","author":"Y Saunthararajah","year":"2007","unstructured":"Saunthararajah Y (2007) Decitabine and sickle cell disease: molecular therapy for a molecular disease. Pediatr Hematol Oncol 24:465\u2013468","journal-title":"Pediatr Hematol Oncol"},{"key":"10_CR119_10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2141.2008.07027.x","volume":"141","author":"Y Saunthararajah","year":"2008","unstructured":"Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J (2008) Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol 141:126\u2013129","journal-title":"Br J Haematol"},{"key":"10_CR120_10","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-06-0669","volume":"12","author":"DS Schrump","year":"2006","unstructured":"Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12:5777\u20135785","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10_CR121_10","first-page":"28","volume":"11","author":"G Schwartsmann","year":"1997","unstructured":"Schwartsmann G, Fernandes MS, Schaan MD, Moschen M, Gerhardt LM, DiLeone L, Loitzembauer B, Kalakun L (1997) Decitabine (5-aza-2\u2019-deoxycytidine; decitabine) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 11(Suppl 1):28\u201331","journal-title":"Leukemia"},{"key":"10_CR122_10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1006388031954","volume":"18","author":"G Schwartsmann","year":"2000","unstructured":"Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, DiLeone L, Mans DR (2000) A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18:83\u201391","journal-title":"Invest New Drugs"},{"key":"10_CR123_10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.exphem.2006.10.005","volume":"35","author":"SA Scott","year":"2007","unstructured":"Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF (2007) Zebularine inhibits human acute myeloid leukemia cell growth vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 35:263\u2013273","journal-title":"Exp Hematol"},{"key":"10_CR124_10","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.urology.2007.11.029","volume":"71","author":"D Shang","year":"2008","unstructured":"Shang D, Liu Y, Matsui Y, Ito N, Nishiyama H, Kamoto T, Ogawa O (2008) Demethylating agent 5-aza-2\u2019-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin. Urology 71:1220\u20131225","journal-title":"Urology"},{"key":"10_CR125_10","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/blood-2002-08-2466","volume":"101","author":"L Shen","year":"2003","unstructured":"Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G (2003) Aberrant DNA methylation of p57KIP2 identifies a cell cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101:4131\u20134136","journal-title":"Blood"},{"key":"10_CR126_10","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/0008-5472.CAN-07-0572","volume":"67","author":"J Shi","year":"2007","unstructured":"Shi J, Zhao Y, Ishii T, Hu W, Sozer S, Zhang W, Bruno E, Lindgren V, Xu M, Hoffman R (2007) Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res 67:6417\u20136424","journal-title":"Cancer Res"},{"key":"10_CR127_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00002371-200201000-00002","volume":"25","author":"L Sigalotti","year":"2002","unstructured":"Sigalotti L, Coral S, Nardi G, Spessotto A, Cortini E, Cattarossi I, Colizzi F, Altomonte M, Maio M (2002) Promoter methylation controls the expression fo MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother 25:16\u201326","journal-title":"J Immunother"},{"key":"10_CR128_10","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1158\/0008-5472.CAN-04-1442","volume":"64","author":"L Sigalotti","year":"2004","unstructured":"Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M (2004) Intratumor heterogeneity of cancer\/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2\u2019-deoxycytidine. Cancer Res 64:9167\u20139171","journal-title":"Cancer Res"},{"key":"10_CR129_10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.seminoncol.2005.07.005","volume":"32","author":"L Sigalotti","year":"2005","unstructured":"Sigalotti L, Coral S, Fratta E, Lamaj E, Danielli R, Di Giacomo AM, Altomonte M, Maio M (2005) Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin Oncol 32:473\u2013478","journal-title":"Semin Oncol"},{"key":"10_CR130_10","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302\u20132308","journal-title":"Blood"},{"key":"10_CR131_10","first-page":"339","volume":"15","author":"F Sorm","year":"1968","unstructured":"Sorm F, Vesely J (1968) Effect of 5-aza-2\u2019-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15:339\u2013343","journal-title":"Neoplasma"},{"key":"10_CR132_10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/sj.bjc.6604932","volume":"100","author":"N Steele","year":"2009","unstructured":"Steele N, Finn P, Brown R, Plumb JA (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene reexpression and drug sensitivity in vivo. Br J Cancer 100: 758\u2013763","journal-title":"Br J Cancer"},{"key":"10_CR133_10","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1158\/0008-5472.CAN-05-2821","volume":"66","author":"C Stresemann","year":"2006","unstructured":"Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F (2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66:2794\u20132800","journal-title":"Cancer Res"},{"key":"10_CR134_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Lyko F (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8\u201313","journal-title":"Int J Cancer"},{"key":"10_CR135_10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/030089169808400120","volume":"84","author":"A Thibault","year":"1998","unstructured":"Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D (1998) A phase-II study of 5-aza-2\u2019-deoxycytidine (decitabine) in hormone-independent metastatic (D2) prostate cancer. Tumori 84:87\u201389","journal-title":"Tumori"},{"key":"10_CR136_10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.seminoncol.2005.07.003","volume":"32","author":"M Toyota","year":"2005","unstructured":"Toyota M, Issa JP (2005) Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32:521\u2013530","journal-title":"Semin Oncol"},{"key":"10_CR137_10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2141.2008.07482.x","volume":"144","author":"S Trompeter","year":"2009","unstructured":"Trompeter S, Roberts I (2009) Haemoglobin F modulation in childhood sickle cell disease. Brit J Haematol 144:308\u2013316","journal-title":"Brit J Haematol"},{"key":"10_CR138_10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.leukres.2003.11.016","volume":"28","author":"J van den Bosch","year":"2004","unstructured":"van den Bosch J, L\u00fcbbert M, Verhoef G, Wijermans PW (2004) The effects of 5-aza-2\u2019-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndrome. Leuk Res 28:785\u2013790","journal-title":"Leuk Res"},{"key":"10_CR139_10","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/cncr.22652","volume":"109","author":"S Venturelli","year":"2007","unstructured":"Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M (2007) Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 109: 2132\u201341","journal-title":"Cancer"},{"key":"10_CR140_10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0277-5379(91)90493-W","volume":"27","author":"JB Vermorken","year":"1991","unstructured":"Vermorken JB, Tumolo S, Roozendaal KJ, Guastalla JP, Splinter Ted AW, Renard J (1991) 5-Aza-2\u2019-deoxycytidine in advanced or recurrent cancer of the uterine cervix. Eur J Cancer 27:216\u2013217","journal-title":"Eur J Cancer"},{"key":"10_CR141_10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.0007-1048.2001.03319.x","volume":"116","author":"JC Wang","year":"2002","unstructured":"Wang JC, Chen W, Nallusamy S, Chen C, Novetsky AD (2002) Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Brit J Haematol 116:582\u2013586","journal-title":"Brit J Haematol"},{"key":"10_CR142_10","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1517\/14656560802519878","volume":"9","author":"WC Wang","year":"2008","unstructured":"Wang WC (2008) The pharmacotherapy of sickle cell disease. Expert Opin Pharmacother 9: 3069\u20133082","journal-title":"Expert Opin Pharmacother"},{"key":"10_CR143_10","first-page":"1766","volume":"54","author":"J Weber","year":"1994","unstructured":"Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA (1994) Expression of the MAGE-I tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2019-deoxycytidine. Cancer Res 54:1766\u20131771","journal-title":"Cancer Res"},{"key":"10_CR144_10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00002371-200103000-00010","volume":"24","author":"TS Weiser","year":"2001","unstructured":"Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS (2001a) Sequential 5-aza-2\u2019-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-I. J Immunother 24:151\u2013161","journal-title":"J Immunother"},{"key":"10_CR145_10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0003-4975(00)02421-8","volume":"71","author":"TS Weiser","year":"2001","unstructured":"Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, Nguyen DM, Schrump DS (2001b) Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 71:295\u2013301","journal-title":"Ann Thorac Surg"},{"key":"10_CR146_10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.leu.2400526","volume":"11","author":"PW Wijermans","year":"1997","unstructured":"Wijermans PW, Krulder JW, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-Aza-2\u2019-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11: 19\u201323","journal-title":"Leukemia"},{"key":"10_CR147_10","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","volume":"18","author":"PW Wijermans","year":"2000","unstructured":"Wijermans PW, L\u00fcbbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2\u2019-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18: 956\u2013962","journal-title":"J Clin Oncol"},{"key":"10_CR148_10","unstructured":"Wijermans PW, L\u00fcbbert M, Verhoef G (2002) Low dose decitabine for elderly high risk MDS patients: who will respond ? Blood 100:96a (abstract 355)"},{"key":"10_CR149_10","doi-asserted-by":"crossref","unstructured":"Wijermans P, Suciu S, Baila L, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Salih H, Beeldens F, Muus P, de Witte T, L\u00fcbbert M (2008) Low dose Decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Group. Blood:112 (abstract 226)","DOI":"10.1182\/blood.V112.11.226.226"},{"issue":"Suppl 1","key":"10_CR150_10","first-page":"49","volume":"7","author":"R Willemze","year":"1993","unstructured":"Willemze R, Archimbaud E, Muus P (1993) Preliminary results with 5-aza-2\u2019deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC leukemia cooperative group. Leukemia 7(Suppl 1):49\u201350","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10_CR151_10","first-page":"24","volume":"11","author":"R Willemze","year":"1997","unstructured":"Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, Berneman Z, Tjean M, Wijermans P, D\u00f6hner H, Jehn U, Labar B, Jaksic B, Dardenne M, Zittoun R (1997) A randomized phase-II study on the effects of 5-aza-2\u2019-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC leukemia cooperative group phase-II study. Leukemia 11(Suppl 1):24\u201327","journal-title":"Leukemia"},{"key":"10_CR152_10","first-page":"3493","volume":"43","author":"VL Wilson","year":"1983","unstructured":"Wilson VL, Jones PA, Momparler RL (1983) Inhibition of DNA methylation in L1210 leukemia cells by 5-aza-2\u2019-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 43:3493\u20133496","journal-title":"Cancer Res"},{"key":"10_CR153_10","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/leu.2009.58","volume":"23","author":"L Yanez","year":"2009","unstructured":"Yanez L, Bermudez A, Richard C, Bureo E, Iriondo A (2009) Letter to the editor: Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Leukemia 23:1342\u20131343","journal-title":"Leukemia"},{"key":"10_CR154_10","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1158\/0008-5472.CAN-05-2385","volume":"66","author":"AS Yang","year":"2006","unstructured":"Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP (2006) DNA methylation changes after 5-aza-2\u2019-deoxycytidine therapy in patients with leukemia. Cancer Res 66:5495\u20135503","journal-title":"Cancer Res"},{"key":"10_CR155_10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","volume":"29","author":"H Yang","year":"2005","unstructured":"Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G (2005) Antileukemia activity of the combination of 5-aza-2\u2019-deoxycytidine with valproic acid. Leuk Res 29:739\u2013748","journal-title":"Leuk Res"},{"key":"10_CR156_10","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood-2008-02-141002","volume":"113","author":"H Yang","year":"2009","unstructured":"Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O\u2019Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G (2009) Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113:1892\u20131898","journal-title":"Blood"},{"key":"10_CR157_10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrd1930","volume":"5","author":"CB Yoo","year":"2006","unstructured":"Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37\u201350","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR158_10","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/0008-5472.CAN-07-0251","volume":"67","author":"CB Yoo","year":"2007","unstructured":"Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S, Jones PA (2007) Delivery of 5-aza-2\u2019-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 67:6400\u20136408","journal-title":"Cancer Res"},{"key":"10_CR159_10","unstructured":"Zagonel V, Pinto A, Bullian PL, Sorio R, Gattei V, Curri G, De Rosa L, Attadia V, Monfardini S (1990) 5-Aza-2\u2019-deoxycytidine as a differentiation inducer in human hemopoietic malignancies: preliminary clinical report. In: Richard L. Momparler, Dick de Vos (eds) 5-Aza-2\u2019-deoxycytidine: preclinical and clinical studies. PCH, Haarlem, Netherlands, pp 165\u2013181"},{"key":"10_CR160_10","unstructured":"Zagonel V, Lo Re G, Marotta G, Barbare R, Sardeo R, Gattei V, De Angelis V, Montardinni S, Pinto A (1993) 5-Aza-2\u2019-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndrome. Leukemia (Suppl 1): 30\u201335"},{"key":"10_CR161_10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0022-2836(02)00676-9","volume":"23","author":"L Zhou","year":"2002","unstructured":"Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP (2002) Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 23:591\u2013599","journal-title":"J Mol Biol"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-01222-8_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T03:22:17Z","timestamp":1739416937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-01222-8_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"ISBN":["9783642012211","9783642012228"],"references-count":161,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-01222-8_10","relation":{},"ISSN":["0080-0015"],"issn-type":[{"value":"0080-0015","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10,7]]},"assertion":[{"value":"7 October 2009","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}